- Home
- SEER vs SKYE Comparison
SEER vs SKYE Comparison
Compare SEER & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- SKYE
- Stock Information
- Founded
- SEER 2017
- SKYE 2012
- Country
- SEER United States
- SKYE United States
- Employees
- SEER N/A
- SKYE N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- SKYE Health Care
- Exchange
- SEER Nasdaq
- SKYE Nasdaq
- Market Cap
- SEER 129.7M
- SKYE 108.3M
- IPO Year
- SEER 2020
- SKYE N/A
- Fundamental
- Price
- SEER $2.28
- SKYE $2.46
- Analyst Decision
- SEER Hold
- SKYE Buy
- Analyst Count
- SEER 1
- SKYE 6
- Target Price
- SEER $3.00
- SKYE $18.67
- AVG Volume (30 Days)
- SEER 186.8K
- SKYE 209.5K
- Earning Date
- SEER 02-27-2025
- SKYE 02-09-2025
- Dividend Yield
- SEER N/A
- SKYE N/A
- EPS Growth
- SEER N/A
- SKYE N/A
- EPS
- SEER N/A
- SKYE N/A
- Revenue
- SEER $14,608,000.00
- SKYE N/A
- Revenue This Year
- SEER N/A
- SKYE N/A
- Revenue Next Year
- SEER $34.78
- SKYE N/A
- P/E Ratio
- SEER N/A
- SKYE N/A
- Revenue Growth
- SEER N/A
- SKYE N/A
- 52 Week Low
- SEER $1.51
- SKYE $2.25
- 52 Week High
- SEER $2.63
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- SEER 42.84
- SKYE 25.13
- Support Level
- SEER $2.20
- SKYE $2.39
- Resistance Level
- SEER $2.37
- SKYE $3.55
- Average True Range (ATR)
- SEER 0.11
- SKYE 0.33
- MACD
- SEER -0.04
- SKYE -0.06
- Stochastic Oscillator
- SEER 20.45
- SKYE 4.59
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.